SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $7.6 million in its fourth quarter.The Salt Lake City-based company said it had a loss of 10 cents per share. Losses, adjusted for one-time gains and costs, were 2 cents per share.The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for a loss of 2 cents per share.The molecular diagnostic company posted revenue of $160.8 million in the period, falling short of Street forecasts. Four analysts surveyed by Zacks expected $162.2 million.For the year, the company reported that its loss narrowed to $27.2 million, or 35 cents per share. Revenue was reported as $690.6 million.Myriad expects full-year results to range from a loss of 90 cents per share to earnings of 20 cents per share, with revenue in the range of $670 million to $700 million.ADVERTISEMENT_____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN